top of page

Publications

Reply to a letter regarding, “Pharmacists are missing an opportunity to save lives and advance the profession by embracing opioid harm reduction”

J Am Pharm Assoc. 2020. DOI: 10.1016/j.japh.2020.02.019

Hill LG, Evoy KE, Reveles KR. 

Read More

Isotonitazene as a contaminant of concern in the illegal opioid supply: A practical synthesis and cost perspective

Int J Drug Policy. 2020. DOI: 10.1016/j.drugpo.2020.102939

Zagorski CM, Myslinski JM, Hill LG. 

Read More

Lofexidine for acute opioid withdrawal: A clinical case series

Ment Health Clin. 2020. DOI: 10.9740/mhc.2020.09.259

Renfro ML, Loera LJ, Tirado CF, Hill LG.

Read More

Type and extent of opioid-related education provided by U.S. college of pharmacy continuing education divisions

Am J Pharm Educ. 2020. DOI: 10.5688/ajpe8001

Renfro ML, Moczygemba LR, Baumgartner J, Baumgart G, Hill LG.

Read More

Increasing naloxone knowledge and use through direct-to-patient education

J Pharm Technol. 2020. DOI: 10.1177/8755122520954218

Litten K, Hill LG, Garza A, Srinivasa M.

Read More

Report of the 2020 special committee on substance use and pharmacy education

Am J Pharm Educ. 2020. DOI: 10.5688/ajpe8421

Tran T, Ball J, Bratberg JP, DeSimone EM, Franko TS, Hill LG, Koh-Knox Sharp CP, Palombi L, Ventricelli D, Farrell D, Gandhi N, Moore T. 

Read More

Mobilizing pharmacists to address the opioid crisis, a joint opinion of the ambulatory care and adult medicine practice and research networks for the American College of Clinical Pharmacy

J Am Coll Clin Pharm. 2020. DOI: 10.1002/jac5.1331

Coon SA, Hill LG, Hutchison RW, Arnold LM, Jarrett JB, Ottney AR, Oung AB, Painter NA, Smith MA, Stranges PM, Tran TH, McFee Winans AR, Bratberg JP. 

Read More

Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA

Addiction. 2021. DOI: 10.1111/add.15314

Hill LG, Loera LJ, Evoy KE, Torrez SB, Renfro ML, Zagorski CM, Perez JC, Jones SM, Reveles KR. 

Read More

Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19

Am J Health Syst Pharm. 2021. DOI: 10.1093/ajhp/zxab003

Peckham AM, Ball J, Colvard MD, Dadiomov D, Hill LG, Nichols SD, Tallian K, Ventricelli DJ, Tran TH. 

Read More

Considering the potential benefits of over-the-counter naloxone

Integr Pharm Res Pract. 2021. DOI: 10.2147/iprp.S244709

Evoy KE, Hill LG, Davis CS. 

Read More
bottom of page